Head-to-head · WeighScore
Layla vs NowPatient
The verdict
Layla takes it — 70.9/100 to 65.5/100.
Layla grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Layla is a US telehealth weight-loss program built around semaglutide, offering compounded semaglutide as injections and as oral dropper drops, plus compounded tirzepatide and a brand-inclusive GLP-1…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Layla | NowPatient |
|---|---|---|
| WeighScore | 70.9/100 | 65.5/100 |
| Grade | C | C |
| Scorecard rank | #103 | #222 |
| Semaglutide | $237/mo (all doses, compounded) | $1,349/mo (brand Wegovy) |
| Tirzepatide | $199/mo (all doses, compounded) | $1,069/mo (brand Mounjaro, promotional rate) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Graded #103 · C
Strengths
- Oral semaglutide dropper option plus injectable semaglutide and tirzepatide, with a brand-name upgrade path
- Named Medical Director (Dr. Ruth Cohen) and 24-7 doctor messaging
- Quiz-based intake with fast three to five day shipping
Where it loses points
- Brand-inclusive GLP-1 program is expensive, starting around 1,299 dollars
- States served are not published on the site
- Support phone line uses a UK format, and the compounding pharmacy is not named
Graded #222 · C
Strengths
- Free telehealth consultation — you only pay for the medication
- Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
- One of the few platforms offering Wegovy in both injection and oral pill form
- No compounded options — every drug is FDA-approved brand-name
Where it loses points
- Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
- No compounded semaglutide or tirzepatide (usually the cheaper route)
- State availability determined during intake, not shown upfront
- Does not offer Foundayo (orforglipron)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.